$Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors$

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Background: BAY 43-9006, an oral multi-kinase inhibitor, targets serine-threonine kinases and receptor tyrosine kinases, and affects the tumor and vasculature in preclinical models. Based on its pharmacologic effect, it may be a useful cancer treatment. This study determined the maximum tolerated do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2005-10, Vol.16 (10), p.1688-1694
Hauptverfasser:	Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., Schwartz, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents BAY 43-9006 Benzenesulfonates - administration & dosage Benzenesulfonates - adverse effects Benzenesulfonates - pharmacokinetics Benzenesulfonates - therapeutic use Biological and medical sciences Drug Administration Schedule Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Female Humans Male Maximum Tolerated Dose Medical sciences Middle Aged Neoplasms - drug therapy Niacinamide - analogs & derivatives pharmacokinetics Pharmacology. Drug treatments phase I Phenylurea Compounds Pyridines - administration & dosage Pyridines - adverse effects Pyridines - pharmacokinetics Pyridines - therapeutic use safety Sorafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!